Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A phase 3 trial of Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel / nab-paclitaxel, Trastuzumab and Trastuzumab biosimilars in Breast cancer, run by National Cancer Institute (NCI), completed.
Overview
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer is a phase 3 interventional study registered as NCT01275677 by National Cancer Institute (NCI), with 3270 participants recorded, started 2011-02-08 and reaching its primary completion in 2017-07-31. Interventions recorded: Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab. Conditions recorded: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7.
Linked to the drug Trastuzumab biosimilars because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialCombination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Shares Breast cancer (all types), Cyclophosphamide, Trastuzumab, Doxorubicin and the tag pipeline.
- TrialMARGetuximab Or Trastuzumab (MARGOT)
Shares Trastuzumab biosimilars, Breast cancer (all types), Trastuzumab, Paclitaxel / nab-paclitaxel and the tag pipeline.
- TrialDocetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Shares Trastuzumab biosimilars, Docetaxel, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialRadiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Shares Trastuzumab biosimilars, Trastuzumab and the tag pipeline.
- TrialSix vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Shares Docetaxel, Breast cancer (all types), Cyclophosphamide, Trastuzumab and the tag pipeline.
- TrialRandomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Shares Docetaxel, Breast cancer (all types), Cyclophosphamide, Paclitaxel / nab-paclitaxel and the tag pipeline.
- TrialSafety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Shares Docetaxel, Breast cancer (all types), Cyclophosphamide and the tag pipeline.
- TrialSequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
Shares Docetaxel, Breast cancer (all types), Cyclophosphamide and the tag pipeline.